Cardinal Health (CAH) Stock Sinks As Market Gains: Here's Why

Cardinal Health (CAH) recently underperformed the broader market and its sector, declining 1.29% in the latest session. Despite this, the company is projected to report strong upcoming earnings, with consensus estimates forecasting an 18.09% increase in EPS to $2.22 and a 12.96% rise in revenue to $59.05 billion. Analyst sentiment, reflected by a Zacks Rank of #3 (Hold) and a 0.48% upward revision in consensus EPS projections over the past 30 days, suggests a stable outlook, while its valuation indicates a forward P/E premium but a favorable PEG ratio compared to its highly-ranked industry.

Analysis

Cardinal Health (CAH) exhibits a notable divergence between its recent stock performance and its forward-looking fundamental outlook. The stock recently declined 1.29% to $150.27, underperforming the S&P 500's 0.47% gain, and has also lagged both its sector and the broader market over a slightly longer timeframe. Despite this price weakness, consensus estimates point to robust growth, with upcoming quarterly earnings per share (EPS) projected to increase 18.09% year-over-year to $2.22 on a 12.96% revenue increase to $59.05 billion. Full-year estimates are similarly strong, forecasting 14.2% EPS growth and 12.01% revenue growth. This positive outlook is supported by a 0.48% upward revision in consensus EPS projections over the last 30 days. However, the stock's valuation presents a mixed picture; its forward P/E ratio of 16.17 indicates a premium over the industry average of 14.29, but its PEG ratio of 1.29 is favorable compared to the industry's 1.75, suggesting the price may be reasonable relative to its growth prospects. The neutral Zacks Rank of #3 (Hold) reflects this balance between strong growth forecasts and a premium valuation amidst recent market underperformance.

Key Decisions for Investors

• Given the strong double-digit earnings and revenue growth projections, investors may view the recent stock underperformance as a potential entry point, especially as the PEG ratio of 1.29 suggests the valuation is reasonable relative to expected growth.
• The neutral 'Hold' rating and premium forward P/E of 16.17 relative to its industry warrant a degree of caution; it may be prudent to await the upcoming earnings report to validate that the company can execute on its strong growth forecasts before committing new capital.
• Monitor the stock's performance post-earnings, as a failure to meet the high expectations for 18.09% EPS growth could challenge the current valuation and lead to further underperformance relative to its industry peers.